Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Managed Access Programs for PKC412, Midostaurin

Conditions: FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia
Acute Myeloid Leukemia
Aggressive Systemic Mastocytosis
Mast Cell Leukemia
Systemic Mastocytosis With an Associated Hematologic Neoplasm

First Posted Date: 2022-02-02

Last Posted Date: 2024-06-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05219266

A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®

Recruiting

Conditions: Asthma

Interventions: Other: Atectura inhalation capsule (150/80ug)
Other: Atectura inhalation capsule (150/160ug)
Other: Atectura inhalation capsule (150/320ug)

First Posted Date: 2022-02-01

Last Posted Date: 2024-02-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 600

Registration Number: NCT05217810

Locations: 🇰🇷
Novartis Investigative Site, Daegu, Dalseo Gu, Korea, Republic of

Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

Completed

Conditions: Psoriasis Vulgaris
Psoriatic Arthritis
Pustular Psoriasis

Interventions: Other: Cosentyx

First Posted Date: 2022-01-31

Last Posted Date: 2024-11-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT05215561

Locations: 🇯🇵
Novartis Investigative Site, Wakayama, Japan

Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).

Phase 3

Withdrawn

Conditions: Active Peripheral Spondyloarthritis (pSpA)

Interventions: Biological: Secukinumab
Other: Placebo

First Posted Date: 2022-01-25

Last Posted Date: 2023-01-09

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05206591

Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)

Phase 1

Terminated

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: MHS552
Drug: Placebo

First Posted Date: 2022-01-24

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT05203419

Locations: 🇩🇪
Novartis Investigative Site, Berlin, Germany

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Phase 2

Recruiting

Conditions: Leukemia, Myelomonocytic, Chronic
Myelodysplastic Syndromes

Interventions: Drug: sabatolimab
Drug: decitabine
Drug: INQOVI (oral decitabine)
Drug: azacitidine
Drug: spartalizumab
Drug: venetoclax

First Posted Date: 2022-01-21

Last Posted Date: 2024-12-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 70

Registration Number: NCT05201066

Locations: 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Uni of Massachusetts Medical Center, Worcester, Massachusetts, United States

and more 3 locations

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM

Phase 2

Terminated

Conditions: Obesity

Interventions: Drug: MBL949
Drug: Placebo

First Posted Date: 2022-01-20

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 126

Registration Number: NCT05199090

Locations: 🇺🇸
Novartis Investigative Site, Dallas, Texas, United States

Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

Phase 4

Active, not recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Biological: Ofatumumab

First Posted Date: 2022-01-20

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 99

Registration Number: NCT05199571

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Treatment A
Drug: Treatment B
Drug: Treatment C

First Posted Date: 2022-01-19

Last Posted Date: 2022-12-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 33

Registration Number: NCT05195892

Locations: 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom

Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

Phase 4

Active, not recruiting

Conditions: Hypercholesterolemia

Interventions: Drug: Placebo
Drug: Inclisiran Sodium

First Posted Date: 2022-01-14

Last Posted Date: 2024-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1775

Registration Number: NCT05192941

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy